The elucidation of the molecule mechanism of the drug susceptibility in the chemotherapy for the oligodendroglioma

点击翻译按钮获取中文摘要

This research investigated deficit of a chromosome (1p, 19q, 10q, CDKN2N), and variation of a gene TP53, and amplification of EGFR or CDK4 in many clinical samples of a tumor bank. Many of tumors accompanied by 1p deficit are oligodendroglioma, and it is in about 60% of the oligodendroglioma. It was simultaneously accompanied by the deficit of 19q. In the oligodendroglioma without the deficit of chromosome 1p, many gene variation of p53 was accepted.Next, the drug susceptibility in chemotherapy related gene of the oligodendroglioma. A profile analysis of chromosome 1p was performed by a microarray (DNA chip) for the purpose of the antioncogene identification assumed to be on chromosome 1p. Consequently, chemotherapy susceptibility is high among oligodendroglioma accompanied by the deficit of single-sided allele of 1p. For the first time 209 genes changing intentionally on chromosome 1p, and the 123 genes considered an antioncogene, were identified.Furthermore, for astrocytoma or glioblastoma gene expression profile analysis was performed by Gene chip, and comparison analysis with the oligodendroglioma was enforced. It became clear that the gene amplified in oligodendroglioma with high chemotherapy susceptibility was the gene cluster to a neuron. Moreover, some genes discovered characteristic of astrocytoma or the glioblastoma were also identified. Although, as for two examples of astrocytoma (WHO Grade II), the discovery profile resembled glioblastoma (WHO Grade IV), the prognosis of these cases was actually poor and, also clinically, showed progress like glioblastoma.Thus, a gene expression profile can serve as a tool which presumes the prognosis of each case.